Valganciclovir (Pre-emptive CMV Therapy)

DRUG2 trials

Sponsors

Hoffmann-La Roche, University of California, San Francisco

Conditions

Cytomegalovirus (CMV)Cytomegalovirus InfectionsKidney DiseasesKidney Transplant; Complications

Phase 3

A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation

CompletedNCT00372229

Hoffmann-La RocheCytomegalovirus Infections

Start: 2006-05-31End: 2015-10-31Updated: 2020-03-11

Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients

RecruitingNCT06798909

University of California, San FranciscoCytomegalovirus (CMV), Kidney Diseases, Kidney Transplant; Complications

Start: 2025-07-22End: 2031-05-31Target: 360Updated: 2026-04-01

Related Papers

No association of genetic variants in TLR4, TNF-α, IL10, IFN-γ, and IL37 in cytomegalovirus-positive renal allograft recipients with active CMV infection—Subanalysis of the prospective randomised VIPP study

PLoS ONE2021-04-163 citations